Nootropics Index - Save on smarter supplements
Nootropics>Choline donors & cholinergic compounds>CDP-Choline
Choline donors & cholinergic compounds

CDP-Choline

Citicoline (cytidine 5-diphosphocholine)

CDP-Choline, also called citicoline, is a choline donor and phospholipid-pathway compound sold as plain citicoline, Cognizin-branded powders/capsules and some medicine-style solution/ampoule listings. Human cognition evidence is limited and population-specific: individual trials have reported selected attention or older-adult memory signals, while EFSA concluded in 2024 that a memory cause-and-effect relationship was not established. Compare products by actual citicoline amount, branded versus generic form, powder/capsule/solution format, and total choline exposure rather than assuming all choline donors are interchangeable.

Focus SupportMemory SupportLearning SupportMental EnergyHealthy AgingCholinergicBioavailability Sensitive
Updated August 2026/6 min read/10 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What CDP-Choline is

2

CDP-Choline is citicoline, a compound that provides choline and cytidine/uridine-pathway substrates after ingestion. In the current catalog it appears as generic citicoline, Cognizin-branded capsules or powders, a choline sample pack ingredient, and medicine-style solution or ampoule listings.

02

Names, aliases and forms

Common NamesCDP-Choline; Citicoline
Scientific Namecytidine 5-diphosphocholine
AbbreviationCDP-choline
Brand NameCognizin
Trade NameCeraxon
03

Mechanisms of action

A choline donor with membrane-phospholipid context

3

Citicoline is metabolized into choline and cytidine-related substrates involved in phosphatidylcholine synthesis and cholinergic biology. That is mechanistic context, not proof of a cognitive effect or a universal cognitive-enhancer claim.

04

Potential effects and evidence map

Citicoline has individual randomized trials reporting selected attention or memory signals in specific populations, often using branded Cognizin at 250 or 500 mg/day. The record is limited: EFSA’s 2024 evaluation found the memory signal unreplicated and did not establish a cause-and-effect relationship. Cognitive-impairment literature should not be turned into disease claims, and product comparison should distinguish citicoline/CDP-choline from alpha-GPC, choline bitartrate, DMAE and medicine-style citicoline solutions.

Effect domainMagnitudeGrade
Memory / learning5
CumulativeConfidence: Medium

One 12-week 500 mg/day citicoline RCT reported selected memory-measure improvements in older adults with age-associated memory impairment.

Note EFSA’s 2024 evaluation found this memory signal unreplicated and did not establish a cause-and-effect relationship.

2/5
C
Focus / attention6
CumulativeConfidence: Medium

250 or 500 mg/day citicoline has selected human attention evidence, but outcomes and populations are specific.

Note Healthy adolescent/attention trials do not equal broad productivity enhancement.

2/5
B
Mental energy / wakefulness7
AcuteConfidence: Low

Mental-energy claims are weaker and can be confounded by combination products such as citicoline plus caffeine.

Note Do not attribute caffeine-combination results to citicoline alone.

1/5
D
Cellular / long-term brain support3
CumulativeConfidence: Medium

Citicoline has plausible phospholipid and choline-pathway support, but long-term brain-health claims remain uncertain.

Note Clinical impairment reviews should not become prevention claims.

2/5
C
05

Typical dosages and timing

Typical
250-500 mg/day
Not a recommendation
Lower bound
250 mg
Profile value
Upper bound
500 mg
Profile value
Study / label context6Form-specific study context

An attention trial used 250 mg or 500 mg/day of citicoline. This is a label-comparison anchor, not a recommendation, and it should not make medicine-style oral solutions, 1000 mg ampoule names, or mixed sample packs look equivalent to ordinary supplement capsules.

06

Timing & effect horizon

Effect horizonCumulative
Cumulative
Study window4Cumulative
12 weeks
Studied over weeks, not minutes4

The healthy older-adult memory trial used 500 mg/day for 12 weeks. That trial window is not an acute onset promise or a recommended course.

07

Safety, side effects and risk profile

Medicine-label safety context10
A Spanish citicoline medicine label lists very rare reactions including headache, vertigo, nausea, vomiting and occasional diarrhea. Frequency and formulation may differ for supplement products.
Pregnancy data are insufficient10
A Spanish citicoline medicine label reports insufficient pregnancy data and advises use only when clearly necessary. This is a pregnancy-specific medicine-label caution, not a statement about dietary choline requirements or every citicoline supplement.
Condition-specific medicine-label contraindication10
The Spanish citicoline oral-solution medicine label lists parasympathetic nervous-system hypertonia as a contraindication. This is a condition-specific medicine-label warning, not a general healthy-adult risk claim or a statement about every citicoline supplement.
Total choline exposure still matters1
NIH choline guidance is about total choline intake from food and supplements. CDP-Choline provides choline but is not interchangeable with a full dietary choline plan, and high total choline intake can have side effects.
GI discomfort10
Confidence: High

Nausea, vomiting or occasional diarrhea are listed as very rare reactions on a Spanish citicoline medicine label.

Note This medicine-label frequency may not predict every supplement product or dose.

1/5
B
Headache / dizziness10
Confidence: High

Headache and vertigo are listed as very rare reactions on a Spanish citicoline medicine label.

Note Citicoline was generally well tolerated in the 12-week healthy older-adult RCT.

1/5
B
Interaction risk10
Confidence: High

A Spanish citicoline medicine label says citicoline can enhance L-Dopa effects and should not be combined with meclofenoxate.

Note This is a specific medicine-label warning, not evidence for broad interaction claims across racetams, nicotine, caffeine or all neurologic medicines.

3/5
B
Legal / regulatory risk10
Confidence: High

Citicoline product status and permitted claims vary by jurisdiction and product category.

Note Use U.S. supplement rules only for U.S.-market products and medicine monographs only for their listed jurisdiction.

1/5
B
Evidence uncertainty4
Confidence: High

Human evidence is selected, population-specific and not a general productivity claim.

Note The healthy older-adult memory RCT used 500 mg/day for 12 weeks; other claims need their own evidence.

2/5
C
08

Interactions and cautions

Medicine-label context10

A Spanish citicoline medicine label says citicoline can enhance the effects of L-Dopa and should not be given with meclofenoxate. This is specific to that medicine label and does not establish broad interaction claims for caffeine, racetams, nicotine or every neurologic medicine.

09

Legal and regulatory status

United States, 20269

For products marketed in the United States as dietary supplements, FDA explains that supplements are not pre-approved for safety or effectiveness before sale. This is a U.S. product-category rule, not a statement that every citicoline product has the same status worldwide.

10

Practical buying and quality notes

  • Compare generic citicoline, branded ingredients and solution-style listings by labeled citicoline amount, form, serving count and normalized price within the same form. Do not treat a capsule, powder and medicine-style solution as interchangeable solely because their names mention citicoline.2
  • Prefer clear citicoline identity, branded-ingredient documentation where claimed, assay or COA support, serving-size math and separation from other choline donors. A sample pack that includes alpha-GPC, choline bitartrate, DMAE and citicoline should not be compared as pure CDP-Choline.2
11

FAQ

Is CDP-Choline the same as citicoline?

2

Yes for practical product-comparison purposes. CDP-Choline and citicoline are names for cytidine diphosphocholine, though labels may also use branded names such as Cognizin or medicine-style trade names.

What CDP-Choline dose should I compare?

6

Use 250-500 mg/day as a study-and-label comparison range. Compare capsules, powders and solutions by actual citicoline amount, not simply by total package weight or choline category.

Is CDP-Choline better than alpha-GPC?

3

This page should not rank them as universally better or worse. CDP-Choline has a different choline/cytidine pathway and evidence base, so compare by intended use, dose, tolerance, form and total choline exposure.

Can CDP-Choline be used with caffeine or racetams?

7

This page does not establish the safety or benefit of a CDP-Choline stack. One attention study tested a beverage containing citicoline plus caffeine, so its results cannot show what citicoline alone contributes; direct evidence for racetam stacks is limited.

What is known about pregnancy and CDP-Choline?

10

A Spanish citicoline medicine label says there are insufficient data in pregnancy and advises use only when clearly necessary. That medicine-label caution is pregnancy-specific, is not a substitute for dietary choline guidance, and does not establish safety for citicoline supplements in pregnancy.

What should I check before buying CDP-Choline?

2

Check whether the product is generic citicoline or Cognizin, the citicoline amount per serving, powder versus capsule versus solution format, serving count, COA/assay support, other choline donors in the product, and whether it is a medicine-style listing.

12

References

  1. NIH Office of Dietary Supplements. Choline: Fact Sheet for Health Professionals.
  2. PubChem. Citicoline / CDP-choline (CID 13804).
  3. Synoradzki K, Grieb P. Citicoline: A Superior Form of Choline? Nutrients. 2019.
  4. Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and memory function in healthy older adults. J Nutr. 2021.
  5. EFSA NDA Panel. 'Citicoline' and support of the memory function: Evaluation of a health claim. EFSA Journal. 2024.
  6. McGlade E, Agoston AM, DiMuzio J, et al. Citicoline supplementation and attention/motor speed in adolescent males. J Atten Disord. 2015.
  7. Bruce SE, Werner KB, Preston BF, Baker LM. Citicoline-caffeine beverage and attention in healthy adults. Int J Food Sci Nutr. 2014.
  8. Gareri P, Castagna A, Cotroneo AM, Putignano S, Conforti R, De Sarro G. The role of citicoline in cognitive impairment. Clin Interv Aging. 2015.
  9. U.S. Food and Drug Administration. Information for Consumers on Using Dietary Supplements.
  10. Spanish Agency for Medicines and Medical Devices (AEMPS). Citicolina Cinfa 1000 mg oral solution EFG: product information.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.